Clinical operations field note
How to Evaluate an Oncology CRA: Judgment, Escalation and Follow-Through
Evaluate oncology CRA judgment using protocol-specific scenarios, escalation decisions, relevant role ownership, and follow-through.
By Lampgen Clinical Research
Updated

2 min read · estimated
An oncology CRA assessment should connect prior experience with the decisions and responsibilities in the new assignment. Start with the protocol and the work: screening, monitoring, safety follow-up, site communication, and the actions that need sustained ownership.
ICH E6(R3) addresses monitor qualifications, risk-based monitoring, reporting, and sponsor oversight. The interview approach below is Lampgen’s practical application of those principles; it is not a regulator-prescribed interview or evidence that a staffing provider guarantees trial performance.
Write the assignment before judging the résumé
Describe the study phase, treatment context, assigned sites, expected travel, relevant systems, upcoming decisions, and sponsor review process. Identify what the CRA will own and which matters must move to the investigator, medical monitor, CTM, or sponsor.
A tumor-type match is useful context. It does not establish whether someone has handled dose-escalation documentation, central laboratory dependencies, complex source review, or ongoing follow-up after treatment stops. Ask about the relevant responsibility directly.
Ask for the decision behind a finding
- What did you observe, and how did you establish the protocol requirement?
- What made the issue consequential for participant protection or reliable study information?
- Who needed to decide, and what information did you give that person?
- What did the site understand about the next action?
- How did you document follow-up and check whether the action worked?
Use an operating scenario without requesting confidential records
Consider a hypothetical screening visit with a required outside pathology report still pending. Ask the candidate to explain how they would establish the current status, identify the responsible site contact, document the gap, and escalate through the monitoring plan before an eligibility decision is due. The investigator remains responsible for the clinical eligibility assessment.
Use a de-identified discussion or a fictional case. Evaluate the reasoning and the professional’s personal responsibility; do not ask for patient records or another sponsor’s confidential documents. A fluent answer still needs the appropriate role, reference, and qualification checks agreed for the assignment.
Match the result to an onboarding plan
Identify the experience the professional brings and the training or supervision the assignment requires. Agree on report review, escalation contacts, current study documents, system access, and backup coverage before the start date.
Lampgen Clinical Research scopes oncology CRA staffing around those responsibilities. Availability, assignment fit, and engagement terms are confirmed separately. Staffing supports the sponsor’s monitoring strategy; it does not transfer the sponsor’s retained oversight or guarantee an outcome.